Pharmacotherapy for older adults with cancer: a digest of the Japanese clinical practice guidelines (2nd edition) - lung cancer

Scritto il 06/11/2026
da Toshio Kubo

Int J Clin Oncol. 2026 Nov 6. doi: 10.1007/s10147-026-03242-5. Online ahead of print.

ABSTRACT

BACKGROUND: The number of older adults with lung cancer is increasing in aging societies. However, determining optimal pharmacotherapy remains challenging because of heterogeneity in functional status, comorbidities, and the limited representation of older adults in clinical trials.

METHODS: This article presents an English digest of the second edition of the Japanese Clinical Practice Guidelines for Pharmacotherapy in Older Adults with Cancer, focusing on lung cancer. The guidelines were developed using the Minds 2020 methodology and incorporated systematic reviews, an evidence-to-decision framework, and multidisciplinary expert consensus.

RESULTS: These guidelines address key clinical questions in small-cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC), including prophylactic cranial irradiation, adjuvant therapy, and immune checkpoint inhibitor-based treatments. Most recommendations were conditional, and no recommendation could be made for several clinical questions because of limited evidence in older populations. Prophylactic cranial irradiation may reduce brain metastases in selected patients with SCLC but requires careful consideration of potential neurocognitive toxicity. In resected NSCLC, tegafur-uracil may be an option for selected older patients; however, evidence supporting platinum-based chemotherapy and immunotherapy remains insufficient. In advanced NSCLC, immune checkpoint inhibitor monotherapy may benefit selected patients, whereas the role of chemoimmunotherapy remains uncertain because of insufficient age-specific evidence.

CONCLUSIONS: These guidelines provide practical, evidence-based recommendations for pharmacotherapy in older adults with lung cancer. They emphasize individualized treatment strategies based on patient characteristics, treatment goals, and tolerability. Further research in older populations is required to strengthen the evidence base for geriatric oncology.

PMID:42993236 | DOI:10.1007/s10147-026-03242-5